Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lippia origanoides hydroalcoholic extract is a **botanical extract** derived from the leaves of *Lippia origanoides* Kunth and has been studied as an experimental oral phytomedicine for **diabetes mellitus** and related cardiometabolic complications. In preclinical alloxan-diabetic rat models, the extract showed hypoglycemic, hypolipidemic, antioxidant, hepatic-protective, and renal-protective effects. Its pharmacology appears to be **multicomponent and polypharmacologic**, with flavonoids identified as likely active constituents; proposed mechanisms include **stimulation of insulin release** and **inhibition of alpha-glucosidase**, rather than a single defined molecular target. Additional preclinical literature also describes antinociceptive, analgesic, and anti-inflammatory activity. The agent appears to remain a **research-stage natural product** with no clearly identified commercial developer, approved product, or standardized pharmaceutical formulation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lippia origanoides hydroalcoholic extract.